Halving the Odds: What Genmab's Petosemtamab Phase 3 Win Means for Head and Neck Cancer

Head and neck squamous cell carcinoma is not a disease that has rewarded optimism. For patients with recurrent or metastatic disease, the treatment landscape has been largely static for years. Pembrolizumab, Merck's checkpoint inhibitor, became the standard of care in PD-L1-positive first-line disease after demonstrating an overall survival benefit, and the field has been searching for something that could meaningfully improve on it ever since. That search has produced a long list of failures. On October 28, 2026, Genmab announced that it had produced something different.

The Phase 3 LiGeR-HN1 trial, evaluating petosemtamab in combination with pembrolizumab versus pembrolizumab alone in patients with PD-L1-positive recurrent or metastatic HNSCC, met both of its co-primary endpoints at the first interim analysis. The combination reduced the risk of death by 50%, with a hazard ratio of 0.50 and a p-value below 0.0001. The odds of achieving an objective response were 3.17 times higher with the combination than with pembrolizumab alone. The independent data monitoring committee reviewed the results and the trial was unblinded. Genmab described it as the first positive Phase 3 study in this patient population in several years.

What Petosemtamab Actually Does

Petosemtamab is a bispecific antibody, but not the kind that engages T cells. It is an IgG1 bispecific that simultaneously targets two proteins on tumor cells: epidermal growth factor receptor, a well-established oncology target, and leucine-rich repeat-containing G-protein-coupled receptor 5, known as LGR5. The LGR5 target is what makes petosemtamab mechanistically interesting. LGR5 is expressed on a population of cancer stem-like cells that are implicated in tumor initiation, treatment resistance, and recurrence. These are the cells that conventional EGFR-targeting agents largely leave intact, and their persistence is one of the reasons that EGFR-directed therapies in HNSCC have historically produced responses that do not last.

Petosemtamab works through three distinct mechanisms. Binding to EGFR blocks ligand binding and inhibits downstream signaling regardless of LGR5 expression. In tumor cells that co-express both targets, simultaneous binding to LGR5 and EGFR enables degradation of EGFR through the natural internalization process of LGR5, a mechanism that is not available to conventional EGFR antibodies. And the drug's active Fc domain facilitates destruction of tumor cells by natural killer cells through antibody-dependent cell-mediated cytotoxicity. The combination of these three mechanisms, layered on top of pembrolizumab's checkpoint inhibition, appears to produce an effect that neither agent achieves alone.

The Context the Numbers Require

A hazard ratio of 0.50 in a randomized Phase 3 trial against an active comparator is a striking result by any standard. Pembrolizumab monotherapy is not a weak control arm. It is a drug that has demonstrated overall survival benefit in this disease and has been the standard of care for years. Beating it by 50% in a randomized trial, with a p-value that leaves no room for statistical ambiguity, is a different category of achievement from the incremental improvements that have characterized most recent attempts to improve on checkpoint inhibitor monotherapy in solid tumors.

The HNSCC patient population that LiGeR-HN1 enrolled is one with genuinely limited options. Recurrent or metastatic disease is associated with a median overall survival of approximately 10 to 12 months even with current treatment. Approximately 50% of patients with locally advanced disease will experience recurrence following initial treatment. The disease disproportionately affects men, is associated with tobacco and alcohol use as well as HPV infection, and carries a significant symptom burden given its location in the oral cavity, pharynx, and larynx. The LiGeR-HN1 result is notable for demonstrating benefit regardless of HPV status, which means the drug's activity is not confined to the immunologically favorable HPV-positive subset.

The Acquisition That Made This Possible

Petosemtamab came to Genmab through its $8 billion acquisition of Merus, a Dutch bispecific antibody company, completed in 2025. At the time, the deal was viewed as a significant bet on a drug that had shown impressive Phase 2 data but had not yet demonstrated Phase 3 efficacy. The LiGeR-HN1 result validates that bet in the most direct way possible. William Blair analysts projected $4 billion in peak sales for petosemtamab in HNSCC alone, a figure that does not account for the drug's potential in colorectal cancer, where Genmab is running two additional Phase 3 studies.

The Merus acquisition also illustrates a broader dynamic in oncology dealmaking. The LGR5 target was not on most companies' radar as a priority when Merus began developing petosemtamab. The hypothesis that simultaneously targeting EGFR and cancer stem-like cells expressing LGR5 could produce durable responses in a disease where EGFR monotherapy had repeatedly disappointed was a scientific bet that required years of development to test. The Phase 3 result suggests the hypothesis was correct, and that the $8 billion price tag may look reasonable in retrospect.

What Comes Next

Genmab has indicated it will engage global regulatory authorities and submit the full LiGeR-HN1 dataset for presentation at a future medical meeting. The topline announcement does not include the full safety data or the magnitude of the progression-free survival benefit, which will matter for how oncologists and regulators interpret the totality of the evidence. The drug already holds FDA Breakthrough Therapy Designation for first-line PD-L1-positive HNSCC in combination with pembrolizumab, which should facilitate an expedited regulatory review once a submission is filed.

The broader implications extend beyond HNSCC. Petosemtamab's mechanism, targeting cancer stem-like cells through LGR5 while simultaneously blocking EGFR signaling, is theoretically applicable to any tumor type where both targets are expressed. Colorectal cancer is the next major indication in development, with two Phase 3 trials underway. The LGR5 target is expressed in colorectal cancer stem cells, and the rationale for combining EGFR and LGR5 blockade in that setting is at least as strong as it was in HNSCC before the LiGeR-HN1 data arrived.

For patients with recurrent or metastatic HNSCC, the LiGeR-HN1 result represents the most significant advance in first-line treatment in years. A 50% reduction in the risk of death, in a disease where the median survival is measured in months, is not a statistical abstraction. It is the difference between a treatment that extends life meaningfully and one that does not. The regulatory path forward will take time, and the full data will need to be scrutinized carefully before petosemtamab becomes a standard of care. But the Phase 3 evidence is now in hand, and it is difficult to argue with a hazard ratio of 0.50.